摘要
[目的]比较关节腔内注射医用几丁糖联合肩关节镜下松解术与单纯肩关节镜下松解术治疗原发性冻结肩的临床疗效。[方法]选取2014年6月～2015年12月本院收治的原发性冻结肩患者46例,均采用肩关节镜下行松解术,根据关节腔内是否注射医用几丁糖将患者分为两组,其中23例患者接受关节镜松解术联合几丁糖关节腔内注射治疗(几丁糖组);另外23例患者仅接受单纯关节镜松解术治疗,未行几丁糖关节腔内注射(非几丁糖组),比较两组术后肩关节疼痛视觉模拟评分(VAS)、美国肩肘外科医师协会(ASES)肩关节功能评分和UCLA肩关节功能评分等评估指标。[结果] 46例患者均顺利完成肩关节镜下松解术。术后1个月随访时,几丁糖组和非几丁糖组患者术后VAS评分、ASES评分、UCLA评分均较术前明显改善,差异有统计学意义(P<0.05)。两组间比较丁糖组VAS评分、ASES评分及UCLA评分均优于非几丁糖组,差异具有统计学意义(P<0.05);术后1年时,两组间VAS评分、ASES评分及UCLA评分差异均无统计学意义(P>0.05)。[结论]肩关节镜下松解术治疗冻结肩可显著提高术后肩关节功能,术中及术后多次联合关节腔内注射医用几丁糖可在一定程度上提高冻结肩短期治疗效果。
[Objective] To compare the clinical outcomes of arthroscopic release combined with or without intra-articular injection of chitosan for primary frozen shoulder. [Methods] From June 2014 to December 2015, 46 patients with primary frozen shoulder underwent arthroscopic release. According to whether or not chitosan injected intraarticularly, the patients were divided into 2 groups, including the chitosan group in which 23 patients received arthroscopic release combined the intraarticular injection of chitosan, the non-chitosan group in which another 23 patients had arthroscopic release only. The visual analogue scales(VAS) of pain, American Shoulder and Elbow Surgeons(ASES) score, as well as University of California at Los Angeles(UCLA) score were compared between the two groups. [Results] All the 46 patients had surgical procedures performed smoothly. At 1 month after operation, the VAS significantly decreased, while the ASES score and UCLA score significantly increased compared with those before operation in the both groups, where were statistically significant between the two time points(P<0.05). Compared between the two groups, the chitosan group was statistically superior to the non-chitosan group regarding to VAS, ASES and UCLA scores at 1 month postoperatively(P<0.05). However, there were on statistical differences in VAS,ASES and UCLA scores between the two groups at 1 year after operation(P>0.05). [Conclusion] Arthroscopic release does significantly enhance the shoulder function for primary frozen shoulder, while it combined with intraarticular injection of chitosan further improve the short term outcome to a certain extent.
引文
[1]Papalia R,Franceschi F,Vasta S,et al.Shoulder stiffness and rotator cuff repair[J].Br Med Bull,2012,104(2):163-174.
[2]He Z,Wang B,Hu C,et al.An overview of hydrogel-based intraarticular drug delivery for the treatment of osteoarthritis[J].Colloids Surf B Biointerfaces,2017,154(1):33-39.
[3]Comblain F,Rocasalbas G,Gauthier S,et al.Chitosan:a promising polymer for cartilage repair and viscosupplementation[J].Biomed Mater Eng,2017,28:S209-S215.
[4]Kang ML,Ko JY,Kim JE,et al.Intra-articular delivery of kartogenin-conjugated chitosan nano/microparticles for cartilage regeneration[J].Biomaterials,2014,35:9984-9994.
[5]张晓星,唐康来,陈光兴,等.关节镜下关节囊松解治疗原发性冻结肩的早期临床随访[J].中国矫形外科杂志,2006,17:1291-1293.
[6]梁兵.几丁糖预防肌腱、骨关节术后粘连的疗效分析[J].蚌埠医学院学报,2001,2001:154.
[7]徐瑞生,尹承慧,王永胜,等.医用几丁糖预防髌骨骨折后膝关节粘连的临床观察[J].中国矫形外科杂志,2001,9(1):91-92.
[8]Kim YS,Lee HJ,Park IJ.Clinical outcomes do not support arthroscopic posterior capsular release in addition to anterior release for shoulder stiffness:a randomized controlled study[J].Am JSports Med,2014,42:1143-1149.
[9]Daley EL,Coleman RM,Stegemann JP.Biomimetic microbeads containing a chondroitin sulfate/chitosan polyelectrolyte complex for cell-based cartilage therapy[J].J Mater Chem B,2015,3:7920-7929.
[10]Arunkumar P,Indulekha S,Vijayalakshmi S,et al.Poly(caprolactone)microparticles and chitosan thermogels based injectable formulation of etoricoxib for the potential treatment of osteoarthritis[J].Mater Sci Eng C Mater Biol Appl,2016,61:534-544.
[11]Jian Xi Lu,Florence Prudhommeaux,Alain Meunier,et al.Effects of chitosan on rat knee cartilages[J].Biomaterials,1999,20:1937-1944.
[12]林蔚,徐欢,吴伟东.透明质酸钠与可吸收医用膜结合肩关节镜下松解术治疗冻结肩的疗效研究[J].中国内镜杂志,2017,12(1):5-8.
[13]Chun Zhang LY,Yan Zhou QZ,Liu S.Chitosan oligosaccharides inhibit IL-1β-induced chondrocyte apoptosis via the P38 MAPKsignaling pathway[J].Glycoconj J,2016:33.
[14]Chen P,Xia C,Mei S,et al.Intra-articular delivery of sinomenium encapsulated by chitosan microspheres and photo-crosslinked GelMA hydrogel ameliorates osteoarthritis by effectively regulating autophagy[J].Biomaterials,2016,81(1):1-13.
[15]Butoescu N,Jordan O,Doelker E.Intra-articular drug delivery systems for the treatment of rheumatic diseases:a review of the factors influencing their performance[J].Eur J Pharm Biopharm,2009,73(2):205-218.
[16]Edwards SH.Intra-articular drug delivery:the challenge to extend drug residence time within the joint[J].Vet J,2011,190(1):15-21.
[17]Oprenyeszk F,Chausson M,Maquet V,et al.Protective effect of a new biomaterial against the development of experimental osteoarthritis lesions in rabbit:a pilot study evaluating the intra-articular injection of alginate-chitosan beads dispersed in an hydrogel[J].Osteoarthritis Cartilage,2013,21:1099-1107.
[18]Shive MS,Stanish WD,McCormack R,et al.BST-CarGel?treatment maintains cartilage repair superiority over microfracture at 5years in a multicenter randomized controlled trial[J].Cartilage,2015,6(1):62-72.
[19]Frappier J,Stanish W,Brittberg M,et al.Economic evaluation of BST-CarGel as an adjunct to microfracture vs microfracture alone in knee cartilage surgery[J].J Med Econ,2014,17(2):266-278.
[20]Sarem M,Moztarzadeh F,Mozafari M,et al.Optimization strategies on the structural modeling of gelatin/chitosan scaffolds to mimic human meniscus tissue[J].Mater Sci Eng C Mater Biol Appl,2013,33:4777-4785.
[21]Chen P,Mei S,Xia C,et al.The amelioration of cartilage degeneration by photo-crosslinked GelHA hydrogel and crizotinib encapsulated chitosan microspheres[J].Oncotarget,2017,8:30235-30251.
